Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)

ClinicalTrials.gov ID: NCT07428499

Public ClinicalTrials.gov record NCT07428499. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 19, 2026, 9:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Extension Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema

Study identification

NCT ID: NCT07428499
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: ADARx Pharmaceuticals, Inc.; Industry
Enrollment: 90 participants

Conditions and interventions

Conditions

Interventions

ADX-324 Dose Level 1 Drug
ADX-324 Dose Level 2 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 1, 2026
Primary completion: Jun 29, 2030
Completion: Jun 29, 2030
Last update posted: Apr 29, 2026

2026 – 2030

United States locations

U.S. sites: 15
U.S. states: 11
U.S. cities: 15

Facility	City	State	ZIP	Site status
ADARx Clinical Site	Litchfield Park	Arizona	85340	Not yet recruiting
ADARx Clinical Site	Little Rock	Arkansas	72205	Not yet recruiting
ADARx Clinical Site	San Diego	California	92122	Not yet recruiting
ADARx Clinical Site	Walnut Creek	California	94598	Not yet recruiting
ADARx Clinical Site	Orlando	Florida	32807	Not yet recruiting
ADARx Clinical Site	Chevy Chase	Maryland	20815	Not yet recruiting
ADARx Clinical Site	Wheaton	Maryland	20902	Not yet recruiting
ADARx Clinical Site	Detroit	Michigan	48202	Not yet recruiting
ADARx Clinical Site	St Louis	Missouri	63141	Not yet recruiting
ADARx Clinical Site	Las Vegas	Nevada	89128	Recruiting
ADARx Clinical Site	New York	New York	10029	Not yet recruiting
ADARx Clinical Site	Cincinnati	Ohio	45236	Not yet recruiting
ADARx Clinical Site	Columbus	Ohio	43235	Not yet recruiting
ADARx Clinical Site	Toledo	Ohio	43617	Not yet recruiting
ADARx Clinical Site	Hershey	Pennsylvania	17033	Not yet recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07428499, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 29, 2026 · Synced May 19, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07428499 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →